The mission at Lipid Genomics is to use a personalized medicine approach to develop novel diagnostics and therapeutics for people with acute and chronic inflammatory diseases.

We have identified a novel connection between the HDL cholesterol gene, SCARB1, and the immune checkpoint inhibitor LAG3. We have shown that people with low plasma levels of LAG3 have increased risk for heart disease.

We believe that our LAG3 diagnostic test will be informative in patient selection for acute inflammatory diseases and cardiovascular adverse events in oncology as well as in chronic inflammatory diseases such as heart disease, especially since residual risk for heart disease exists despite lipid lowering treatment.

The research and discovery work being done at Lipid Genomics supports our passion to find and develop new connections for better health.

Lipid Genomics Partners:

UCONN University